LGVN Stock — Longeveron Inc.: Cash, EV, Pipeline

Share price

$2.49

Market cap

$7.9M

Cash

$18.1M

Enterprise value

-$10.2M

Balance sheet

Cash	$18.1M
Debt	$0.0M
Net cash	$18.1M
Enterprise value	-$10.2M
Basic shares	31.4M shares
Fully diluted shares	38.4M shares
Fully diluted market cap	$95.5M
Cash per share	$0.58

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading LGVN daily closes…

Loading price history…

Pipeline assets

laromestrocel

Phase 2 · Active Modality: cell therapy (allogeneic mesenchymal stem cells)

Aliases Lomecel-B

Partnerships University of Miami (exclusive worldwide license for Aging-related Frailty MSC technology)

Indications

hypoplastic left heart syndrome (HLHS) (Phase 2)
Alzheimer's disease (Phase 2)
pediatric dilated cardiomyopathy (DCM) (Stage not disclosed)
Aging-related Frailty (Stage not disclosed)

Catalysts

— not dated

Status note Lead and only investigational product candidate. ELPIS II: multicenter randomized double-blind controlled Phase 2b trial of laromestrocel as adjunct to second-stage HLHS heart reconstructive surgery (next step after completed 10-patient open-label Phase 1 ELPIS I). A second financing closing is contingent on ELPIS II Phase 2b results demonstrating statistical significance of agreed primary endpoints. AD: following March 2025 Type B FDA meeting, company seeks partnership/non-dilutive funding for proposed single seamless adaptive Phase 2/3. Pediatric DCM and Aging-related Frailty: in clinical development per filing, phases not stated in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Lomecel-B medicinal signaling cells
Lead indication	Hypoplastic Left Heart Syndrome
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04925024	Phase 2	Active, not recruiting	Sponsor	LGVN	—	Hypoplastic Left Heart Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Longeveron Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Logos Global Management	1,287,000	+1,287,000	0.04%	2026-08-14
ADAR1 Capital Management	108,406	-91,594	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

LGVN — Longeveron Inc.